Introduction {#sec1_1}
============

Cerebral amyloid angiopathy (CAA) is a vascular disease with the neuropathological evidence of β-amyloid (Aβ) deposition in the walls of the cortical and leptomeningeal vessels \[[@B1]\]. The clinical presentation includes intracerebral macrohemorrhages and cerebral microbleeds \[[@B2]\]. Cortical superficial siderosis (cSS) occurs in the majority of patients with histopathologically proven CAA \[[@B3]\]. The regional interrelation between Aβ and/or tau depositions and the presence of cSS is not yet understood.

Case Report/Presentation {#sec1_2}
========================

We report on an 80-year-old male patient who suffered a cryptogenic ischemic stroke in the right cerebellum in April 2012. The patient was included in the longitudinal Determinants of Dementia after Stroke (DEDEMAS) study \[[@B4]\] and underwent serial standardized magnetic resonance imaging (MRI) in combination with ^18^F-florbetaben \[[@B5]\] Aβ positron emission tomography (PET) at 6 months according to the study protocol (NCT01334749). Amyloid PET at baseline demonstrated mild positivity. At the follow-up visit in 2015 the patient demonstrated an incident mild cognitive impairment diagnosed by Petersen criteria \[[@B6]\] and an incident focal cSS.A diagnostic lumbar puncture revealed reduced Aβ levels (Aβ~42~ = 279 pg/mL), a reduced Aβ~42/40~ ratio (3.8%), and a normal total tau level (378 pg/mL) in CSF.

The follow-up MRI in 2017 showed a progression of cSS from focal to disseminated and twelve incident cerebral microbleeds restricted to lobar regions in the right hemisphere. Hence, a diagnosis of probable CAA according to modified Boston criteria \[[@B2]\] was made. All cSS-affected sulci were segmented using ITK-Snap for analysis as previously described \[[@B7]\]. The patient further underwent a follow-up Aβ PET and ^18^F-PI2620 tau PET \[[@B8]\] in 2017/2018.

Follow-up Aβ PET 6 years from baseline demonstrated a tremendous increase of fibrillar amyloid deposition predominantly in the contralateral left hemisphere not affected by cSS (Fig. [1a](#F1){ref-type="fig"}). In contrast, tau deposition was predominantly localized to the right hemisphere partly overlapping with brain regions affected by cSS. This was also reflected by plotting asymmetry of tau PET against Aβ PET (Fig. [1b, c](#F1){ref-type="fig"}) demonstrating an opposite dominance of amyloid and tau deposition. We further performed a segmental analysis of single brain regions affected by cSS (Fig. [2a](#F2){ref-type="fig"}) and found that amyloid deposition was not different in the vicinity of cSS compared to other compartments (Fig. [2b](#F2){ref-type="fig"}). In contrast, tau depositions were elevated in the vicinity of cSS-affected regions compared to non-cSS-affected brain regions (Fig. [2b](#F2){ref-type="fig"}).

Discussion/Conclusion {#sec1_3}
=====================

Previous literature has suggested that cSS represents a more severe stage of CAA \[[@B9]\] and is associated with amyloid positivity in patients with probable CAA \[[@B10]\]. However, to the best of our knowledge, there is no data available analyzing the distribution of cSS in association with local amyloid positivity and there is no data at all on cSS and tau pathology. Now, our observations raise the possibility that cSS in probable CAA may be associated with a locally elevated tau pathology but not with increased fibrillar amyloid deposition measured by Aβ PET. However, this hypothesis needs to be proven by clinical studies including histology sampling.
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![Comparison of asymmetries between cSS, β-amyloid (Aβ) and tau. **a** Axial slices show progression of cSS and amyloid positivity between 2012 and 2017/2018 by MRI and PET imaging and tau distribution by PET in 2018. **b** Scatter plot of asymmetry in Aβ PET (2018) in comparison to asymmetry in tau PET for all 23 cortical regions (frontal, parietal, temporal) defined by the Hammers atlas. Asymmetry indices demonstrate predominant tau positivity in the cSS-affected right hemisphere and predominant Aβ positivity in the non-cSS-affected left hemisphere. **c** Statistical comparison of frontal, parietal, and temporal asymmetry indices (AI = (L--R)/(L+R)) between Aβ PET and tau PET. *p* values were derived from a paired Student\'s *t* test. ^18^F-florbetaben Aβ and ^18^F-PI-2620 tau PET were acquired from 90 to 110 min p.i. and from 30 to 60 min p.i., respectively, and each summed to a single static frame. PET values were calculated as standardized uptake value ratios with the cerebellar gray matter (CBL) as a reference region after transformation in the MNI space. cSS segmentation and tau PET images are projected onto the patient\'s 3D T1W sequence. PMOD 3.5 (Basel, Switzerland) was used for all image analysis operations.](crn-0012-0232-g01){#F1}

![Segmental analysis based on cSS. **a** Axial images illustrate delineation of a right temporal cSS area and the definition of cSS-positive (black), cSS-negative (gray), and contralateral segments (white) of the anterolateral inferior temporal lobe, illustrated in PET image data upon the patient\'s T1 MPRAGE MRI. **b** Comparison of PET quantification by standardized uptake value ratios (SUVr) in segmented contralateral (white), cSS-negative (gray), and cSS-positive (black) regional values for Aβ PET and tau PET. A total of 17 cortical regions (defined by the Hammers atlas) affected by cSS were included in the analysis. *p* values were derived from an unpaired Student\'s *t* test. A filter of 5.0 mm was used prior to definition of cSS-positive voxels to account for the lower PET resolution in comparison to that of MRI.](crn-0012-0232-g02){#F2}
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